KPE-00001132

KPE-00001132 is a preclinical small molecule candidate developed by Kemin Pharma, a division of Kemin Industries. It belongs to a series of compounds, often described in patents as carotenoid derivatives (such as those derived from lutein), that were engineered for anti-angiogenic and anti-inflammatory therapeutic applications. Preclinical research indicates that KPE-00001132 inhibits Vascular Endothelial Growth Factor (VEGF)-induced endothelial cell proliferation and suppresses the production of key pro-inflammatory cytokines, including Tumor Necrosis Factor-alpha (TNF-α) and Interleukin-6 (IL-6). The compound was primarily investigated for the treatment of ocular neovascular diseases, such as age-related macular degeneration (AMD) and diabetic retinopathy, as well as systemic inflammatory conditions. Development of the KPE series appears to have stalled as Kemin Industries shifted its human health focus toward nutraceuticals and specialty ingredients.